While Johnson & Johnson’s Cordis withdrew from India, companies such as Abbott Laboratories – Vascular, Boston Scientific Corporation, Medtronic Inc. and other players like Biotronik, Sahajanand Medical Technologies, Meril Life Sciences and Translumina Therapeutics are vying to expand their presence in India through investments in the coronary stent market, according to a research report. Stent sales in India approach half a billion dollars annually according to this report, a number that seems high to the The India Expert. However we do expect double digit growth in India for the next decade.
Boston Scientific Corporation is strengthening its presence in the emerging nations with Brazil, Russia, India and China (BRIC) and recorded 22% growth rate in these countries in the last quarter. Medtronic management is targeting 20% of its revenues from the emerging market eyeing incremental revenues of $2.5 billion over the next 5 years (and this was before the proposed merger with Covidien).
Last updated: December 26th, 2025
